Sign in

Trial result ·

PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This was a later look at the MITO END-3 trial. The trial studied advanced or recurrent endometrial cancer. The analysis was exploratory. It looked at gene changes in tumor samples from 107 people. The test was next-generation sequencing. It focused on PIK3CA. The PI3K pathway is often altered in these cancers.

What they found

TP53, PIK3CA, ARID1A and PTEN were the genes changed most often. Changes in PIK3CA were found in 55 of 107 samples. In all, 68 different PIK3CA changes were seen. 64 were judged pathogenic. The most common ones were in the kinase domain. H1047R was found 11 times. 24 of the 68 changes are predicted to respond to alpelisib. This is from breast cancer data. PIK3CA changes appeared in all The Cancer Genome Atlas groups.

What it means for patients

The authors say PIK3CA changes are frequent in endometrial cancer. They say this makes it a tumor type worth testing PI3K inhibitors in. This would be in clinical trials.

Why it is not certain yet

This was a post hoc analysis. Gene data were studied after the fact. The abstract gives no treatment results. The alpelisib prediction comes from breast cancer literature. Samples came from 107 people.

Source

PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study.

PubMed · PMID 42886889

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Endometrial cancer publications